Loading people...
Charles Dunn is a Principal on the biotech investing team at SV Health Investors, operating across the United Kingdom and the United States. Since joining the firm in 2018, he has focused on forming and funding early-stage clinical biotechnology companies, recently leading an investment to create and launch Draig Therapeutics, which raised $140 million. Dunn currently serves as a Board Director at Imbria Pharmaceuticals and Mestag Therapeutics, having helped incubate and launch the latter. He also holds Board Observer roles at Autifony Therapeutics, EnaraBio, and Pulmocide. Before entering venture capital, he spent three years at Deloitte focusing on life sciences clients, where he officially qualified as a Chartered Accountant. His current professional focus remains on drug discovery and development investments, supported by his academic background in human genetics and molecular biology from University College London.
Charles Dunn is a key member of the investment team at SV Health Investors, where he holds the position of Associate. SV Health Investors is a distinguished venture capital firm with a long-standing commitment to fostering innovation within the global healthcare sector. As an Associate, Charles plays a crucial role in the firm's investment process, contributing to the identification, evaluation, and due diligence of potential portfolio companies.
His investment focus areas align with SV Health Investors' broad mandate, which typically spans across several critical segments of healthcare. This includes groundbreaking advancements in biotechnology, novel pharmaceutical development, innovative medical devices, and transformative digital health solutions. Charles is involved in analyzing market trends, assessing the scientific and commercial viability of new technologies, and supporting companies that aim to address significant unmet medical needs or improve patient outcomes. He is particularly interested in disruptive technologies and business models that have the potential to reshape the future of healthcare delivery and treatment.
While specific details of Charles Dunn's career background are often proprietary, individuals in his role typically possess a strong foundation in finance, science, or healthcare. This often includes prior experience in investment banking, management consulting with a focus on life sciences, or direct involvement in biotech or health tech startups. His background likely equips him with the analytical rigor and industry insight necessary to navigate the complex landscape of venture capital in healthcare. He contributes to the strategic support and growth of portfolio companies, working closely with founders and management teams to help them achieve their milestones.
SV Health Investors has a rich history of backing successful companies that have gone on to make significant impacts in their respective fields. While specific investments directly led or championed by Charles Dunn are typically highlighted through official firm announcements or industry reports, his contributions are integral to the firm's overall investment strategy. He is involved in the rigorous process of vetting companies that demonstrate strong scientific merit, robust intellectual property, and clear pathways to commercialization. His work helps ensure that SV Health Investors continues to identify and support the next generation of healthcare leaders. Charles Dunn's dedication to the healthcare venture capital ecosystem underscores his commitment to driving innovation and delivering value for both patients and investors. His role is vital in supporting the firm's mission to build enduring companies that make a real difference in global health.
Charles Dunn is an Associate at SV Health Investors, a leading venture capital firm focused on healthcare innovation. He plays a key role in identifying and evaluating potential investment opportunities across various healthcare sectors.
Charles Dunn's investment focus, aligned with SV Health Investors, includes early-stage and growth-stage companies in biotechnology, pharmaceuticals, medical devices, and digital health solutions. He supports innovations addressing unmet medical needs and improving patient outcomes.
Charles Dunn works at SV Health Investors, a prominent venture capital firm dedicated to advancing healthcare and life sciences through strategic investments in innovative companies.
